Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635621 | 0.96 | SRC (0.50) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL636712 | 0.93 | SRC (0.49) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL2587027 | 0.84 | SMN1; SMN2 (0.57) | HCRTR1HCRTR2ALDH1A1SMN1; SMN2PDE4D | |
| SCHEMBL2433728 | 0.81 | NFE2L2 (0.54) | NPC1RAB9ANFE2L2CYP1A2 | |
| SCHEMBL2433729 | 0.81 | NFE2L2 (0.54) | NPC1RAB9ANFE2L2CYP1A2 | |
| SCHEMBL1054408 | 0.81 | CCNB2 (0.49) | SRCNPC1RAB9AERN1ALDH1A1 | |
| SCHEMBL2424846 | 0.80 | NFE2L2 (0.56) | NPC1RAB9ANFE2L2ALDH1A1SMN1; SMN2 | |
| SCHEMBL1125257 | 0.80 | SRC (0.58) | SRCNPC1RAB9ATLR2ERN1 | |
| SCHEMBL10265507 | 0.79 | THRB (0.37) | SRCTLR2CA1CA2ALDH1A1 | |
| SCHEMBL638076 | 0.79 | ERN1 (0.42) | SRCTLR2ERN1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2626360-A1 | Process for the preparation of fused pyrimidineone compounds useful as TRPV3 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2013-08-14 | — | — | EP | claimed |
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-03 | — | — | US | claimed |
| EP-2283017-B1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS SA (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8518955-B2 | Fused pyrimidineone compounds as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-08-27 | — | — | US | disclosed |
| EP-2626360-A1 | Process for the preparation of fused pyrimidineone compounds useful as TRPV3 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2013-08-14 | — | — | EP | disclosed |
| CN-103172631-A | Condensed pyrimidine derivative serving as transient receptor potential vanilla 3 (TRRV3) regulator | GLENMARK PHARMACEUTICALS SA | 2013-06-26 | — | — | CN | disclosed |
| CN-103159726-A | Chromene ketone derivative used as transient receptor potential vanillin3 (TRPV3) antagonist | GLENMARK PHARMACEUTICALS SA | 2013-06-19 | — | — | CN | disclosed |
| CN-103159788-A | Condensed imidazole formamide serving as transient receptor potential vanillin 3 (TRPV3) modifier | GLENMARK PHARMACEUTICALS SA | 2013-06-19 | — | — | CN | disclosed |
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2012-05-10 | — | — | US | disclosed |
| EP-2283017-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| EP-2229388-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2010070452-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-06-24 | — | — | WO | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
| WO-2010055384-A1 | CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-05-20 | — | — | WO | disclosed |
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. | 2009-11-19 | — | — | US | disclosed |
| WO-2009130560-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009109987-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | TRPV3, TRPV1, TRPV5 | SRC 3295/4885NPC1 1398/4885RAB9A 1584/4885 |
| US-20090286811-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | SRC 2347/4885NPC1 1334/4885RAB9A 3204/4885 |
| US-20120115886-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | SRC 2347/4885NPC1 1334/4885RAB9A 3204/4885 |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | SRC 2927/4885NPC1 744/4885RAB9A 2769/4885 |
| US-20120108813-A1 | FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV4 | SRC 2347/4885NPC1 1334/4885RAB9A 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.